Public-registry site landscape for NCT07684235, “Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)”, a Obesity study sponsored by Amgen. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07684235 (registry record) |
| Study title | Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) |
| Official title | A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants With Obesity or Overweight |
| Sponsor | Amgen |
| Condition(s) | Obesity; Overweight |
| Phase | PHASE3 |
| Listed sites | 0 |
| Intervention(s) | Maridebart cafraglutide, Placebo |
Patient-friendly overview of this study: eichor.com/study/NCT07684235.
Eichor generates a preliminary site-risk snapshot for NCT07684235 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
